198 related articles for article (PubMed ID: 16643444)
21. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
23. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
Levett D; Middleton P; Cole M; Reid MM
Med Pediatr Oncol; 2001 Mar; 36(3):365-71. PubMed ID: 11241438
[TBL] [Abstract][Full Text] [Related]
24. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
[TBL] [Abstract][Full Text] [Related]
25. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
[TBL] [Abstract][Full Text] [Related]
26. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
van der Velden VH; van Dongen JJ
Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
[TBL] [Abstract][Full Text] [Related]
27. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
[TBL] [Abstract][Full Text] [Related]
28. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
30. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
31. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
Cazzaniga G; Biondi A
Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
[TBL] [Abstract][Full Text] [Related]
32. Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia.
Schwarz AK; Stanulla M; Cario G; Flohr T; Sutton R; Möricke A; Anker P; Stroun M; Welte K; Bartram CR; Schrappe M; Schrauder A
Ann Hematol; 2009 Sep; 88(9):897-905. PubMed ID: 19165483
[TBL] [Abstract][Full Text] [Related]
33. [Establishment of a real time quantitative-PCR assay for detection of TCR VgammaI-Jgamma gene rearrangement in acute lymphoblastic leukemia patients].
Jiang XG; Xu B; Xu WJ; Li B
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):425-8. PubMed ID: 15355697
[TBL] [Abstract][Full Text] [Related]
34. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
Campana D; Coustan-Smith E
Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
[TBL] [Abstract][Full Text] [Related]
35. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia.
Specchia G; Liso A; Pannunzio A; Albano F; Mestice A; Pastore D; Liso V
Haematologica; 2004 Oct; 89(10):1271-3. PubMed ID: 15477219
[TBL] [Abstract][Full Text] [Related]
36. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.
Taube T; Eckert C; Körner G; Henze G; Seeger K
Leuk Res; 2004 Jul; 28(7):699-706. PubMed ID: 15158091
[TBL] [Abstract][Full Text] [Related]
37. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Zuna J; Hrusák O; Kalinová M; Muzíková K; Zörnerová T; Starý J; Trka J
Vnitr Lek; 2000 Aug; 46(8):465-9. PubMed ID: 11048511
[TBL] [Abstract][Full Text] [Related]
38. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.
O'Reilly J; Meyer B; Baker D; Herrmann R; Cannell P; Davies J
Leukemia; 1995 Apr; 9(4):624-7. PubMed ID: 7723395
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
